A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Public ClinicalTrials.gov record NCT07277413. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE892 as Monotherapy and Combination Therapy in Participants With MTAP-Deleted Advanced Solid Tumors
Study identification
- NCT ID
- NCT07277413
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Enrollment
- 260 participants
Conditions and interventions
Conditions
Interventions
- IDE397 Drug
- IDE892 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 3, 2026
- Primary completion
- Apr 29, 2028
- Completion
- Apr 29, 2028
- Last update posted
- Apr 2, 2026
2026 – 2028
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sarah Cannon Research Institute at Florida Cancer Specialists | Orlando | Florida | 32827 | Recruiting |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| Columbia University Irving Medical Center | New York | New York | 10032 | Recruiting |
| Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| START Dallas Fort Worth | Fort Worth | Texas | 76104 | Recruiting |
| MD Anderson | Houston | Texas | 77030 | Recruiting |
| NEXT Oncology Houston | Houston | Texas | 77054 | Recruiting |
| NEXT Oncology Dallas | Irving | Texas | 75039 | Recruiting |
| NEXT Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07277413, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07277413 live on ClinicalTrials.gov.